T1	Participants 58 99	women with locally advanced breast cancer
T2	Participants 248 276	patients with breast cancer.
T3	Participants 616 841	Eligible patients had clinical stage II-III (> or = T2 and/or > or = N1) newly diagnosed breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, and normal cardiac, renal, and liver function. 120 women
T4	Participants 1460 1584	120 patients initially enrolled, one withdrew after signing consent and one patient's baseline bone marrow was not available
T5	Participants 1649 1687	109 bone-marrow samples were available
